Quality characteristics and HPLC detection of phosphodiesterase inhibitors in some herbal capsules indicated for male sexual disorders in Ghana

IF 3.4 Q2 PHARMACOLOGY & PHARMACY Future Journal of Pharmaceutical Sciences Pub Date : 2024-09-11 DOI:10.1186/s43094-024-00693-3
Anita Nana Abla Oscar Akotey, Isaac Kingsley Amponsah, Francis Ackah Armah, Bernard Kofi Turkson, John Nii Addotey, Yaa Asantewaa Osei, Joseph Adu, Rita Akosua Dickson
{"title":"Quality characteristics and HPLC detection of phosphodiesterase inhibitors in some herbal capsules indicated for male sexual disorders in Ghana","authors":"Anita Nana Abla Oscar Akotey,&nbsp;Isaac Kingsley Amponsah,&nbsp;Francis Ackah Armah,&nbsp;Bernard Kofi Turkson,&nbsp;John Nii Addotey,&nbsp;Yaa Asantewaa Osei,&nbsp;Joseph Adu,&nbsp;Rita Akosua Dickson","doi":"10.1186/s43094-024-00693-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Herbal medicines used for male sexual disorders are widespread across the globe and have been noted as likely candidates for adulteration. To assure access to safe and quality herbal products, this study aimed at sampling some herbal capsules indicated for male vitality for quality analytical checks.</p><h3>Methods</h3><p>Herbal capsules sampled from two regions were subjected to physicochemical assessment, using pharmacopeial and regulatory standards. Microbial quality analysis was also performed on the selected products. A validated HPLC method for simultaneous analysis of sildenafil citrate and tadalafil was used to detect and quantify the possible presence of phosphodiesterase inhibitors in the selected products.</p><h3>Results</h3><p>Out of a total of 57 herbal capsules, 19 were indicated for male sexual related illnesses of which only 8 fulfilled the inclusion criteria of being used exclusively for male vitality. The majority (62.5%) of the herbal products failed the weight uniformity test but all of them disintegrated within the acceptable limit of 30 min. The moisture and heavy metal contents were within limits of acceptability. Majority (87.5%) of the herbal products failed the test for the aerobic bacteria count; however, none of the isolated bacteria was pathogenic. Sildenafil citrate was detected in the majority (87.5%) of the herbal products in concentrations of 0.98–33.95 mg/g. Two products contained both sildenafil and tadalafil. High batch-to-batch variability was recorded in some physicochemical parameters and pharmaceutical adulterants.</p><h3>Conclusion</h3><p>High incidence of quality fails and adulteration of herbal capsules for sexual disorders observed means there is a real risk of unintended dosing with phosphodiesterase inhibitors. This represents a public health issue and necessitates tighter monitoring of production standards by the regulator.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00693-3","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-024-00693-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Herbal medicines used for male sexual disorders are widespread across the globe and have been noted as likely candidates for adulteration. To assure access to safe and quality herbal products, this study aimed at sampling some herbal capsules indicated for male vitality for quality analytical checks.

Methods

Herbal capsules sampled from two regions were subjected to physicochemical assessment, using pharmacopeial and regulatory standards. Microbial quality analysis was also performed on the selected products. A validated HPLC method for simultaneous analysis of sildenafil citrate and tadalafil was used to detect and quantify the possible presence of phosphodiesterase inhibitors in the selected products.

Results

Out of a total of 57 herbal capsules, 19 were indicated for male sexual related illnesses of which only 8 fulfilled the inclusion criteria of being used exclusively for male vitality. The majority (62.5%) of the herbal products failed the weight uniformity test but all of them disintegrated within the acceptable limit of 30 min. The moisture and heavy metal contents were within limits of acceptability. Majority (87.5%) of the herbal products failed the test for the aerobic bacteria count; however, none of the isolated bacteria was pathogenic. Sildenafil citrate was detected in the majority (87.5%) of the herbal products in concentrations of 0.98–33.95 mg/g. Two products contained both sildenafil and tadalafil. High batch-to-batch variability was recorded in some physicochemical parameters and pharmaceutical adulterants.

Conclusion

High incidence of quality fails and adulteration of herbal capsules for sexual disorders observed means there is a real risk of unintended dosing with phosphodiesterase inhibitors. This represents a public health issue and necessitates tighter monitoring of production standards by the regulator.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
加纳一些用于治疗男性性功能障碍的草药胶囊中磷酸二酯酶抑制剂的质量特性和高效液相色谱检测
背景用于治疗男性性功能障碍的草药在全球范围内广泛使用,并被认为有可能掺假。为确保获得安全、优质的草药产品,本研究旨在对一些用于男性活力的草药胶囊进行采样,以进行质量分析检查。方法采用药典和监管标准,对从两个地区采样的草药胶囊进行理化评估。还对所选产品进行了微生物质量分析。采用经过验证的高效液相色谱法同时分析枸橼酸西地那非和他达拉非,以检测和量化所选产品中可能存在的磷酸二酯酶抑制剂。结果在总共 57 种草药胶囊中,19 种适用于男性性相关疾病,其中只有 8 种符合专门用于增强男性活力的纳入标准。大多数草药产品(62.5%)未能通过重量均匀性测试,但所有产品都在 30 分钟的可接受限度内崩解。水分和重金属含量均在可接受范围内。大多数(87.5%)的草药产品未能通过需氧细菌计数测试,但分离出的细菌中没有致病菌。大多数(87.5%)草药产品中检测到柠檬酸西地那非,浓度为 0.98-33.95 毫克/克。两种产品同时含有西地那非和他达拉非。结论所观察到的性功能障碍草药胶囊质量不合格和掺假的高发生率意味着确实存在意外服用磷酸二酯酶抑制剂的风险。这是一个公共卫生问题,需要监管机构加强对生产标准的监控。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
44
审稿时长
23 weeks
期刊介绍: Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.
期刊最新文献
Nanocochleate-based delivery of quercetin with enhanced therapeutic potential: formulation, cytotoxicity and pharmacokinetics study Computational and experimental insights into glycyrrhizin-loaded nanostructured lipid carriers: docking, dynamics, design optimization, and anticancer efficacy in lung cancer cells Multifunctional approach with LHRH-mediated PLGA nanoconjugate for site-specific codelivery of curcumin and BCL2 siRNA in mice lung cancer Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod Development, characterization, and assessment of PLAROsomal vesicular system of curcumin for enhanced stability and therapeutic efficacy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1